BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Szabó L, Gergely A, Jakus R, Fogarasi A, Grosz Z, Molnár MJ, Andor I, Schulcz O, Goschler Á, Medveczky E, Czövek D, Herczegfalvi Á. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients. Eur J Paediatr Neurol 2020;27:37-42. [PMID: 32456992 DOI: 10.1016/j.ejpn.2020.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Cortés PL, Verdú DP, Férriz AA, Ñungo-Garzón NC, Domine MC, Sevilla-Mantecón T, Pitarch-Castellano I, Vázquez-Costa JF. Validation of Neuromyotype: A smart keyboard for the evaluation of spinal muscular atrophy patients. Neurologia (Engl Ed) 2022:S2173-5808(22)00083-9. [PMID: 35940531 DOI: 10.1016/j.nrleng.2022.05.001] [Reference Citation Analysis]
2 Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Primers 2022;8:52. [PMID: 35927425 DOI: 10.1038/s41572-022-00380-8] [Reference Citation Analysis]
3 Sarıkaya Uzan G, Paketçi C, Günay Ç, Edem P, Özsoy Ö, Hız Kurul S, Yiş U. The Effect of Nusinersen Therapy on Laboratory Parameters of Patients with Spinal Muscular Atrophy. Neuropediatrics. [DOI: 10.1055/s-0042-1750719] [Reference Citation Analysis]
4 Xu B, Wei C, Hu X, Li W, Huang Z, Que C, Qiu J, Li C, Xiong H. Scoliosis Orthopedic Surgery Combined With Nusinersen Intrathecal Injection Significantly Improved the Outcome of Spinal Muscular Atrophy Patient: A Case Report. Front Neurol 2022;13:869230. [PMID: 35547367 DOI: 10.3389/fneur.2022.869230] [Reference Citation Analysis]
5 Tscherter A, Rüsch CT, Baumann D, Enzmann C, Hasselmann O, Jacquier D, Jung HH, Kruijshaar ME, Kuehni CE, Neuwirth C, Stettner GM, Klein A, Jung AH, Lötscher N, Ramelli GP, Ripellino P, Scheidegger O, Wille D. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland. Neuromuscular Disorders 2022. [DOI: 10.1016/j.nmd.2022.02.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 MacCannell D, Berger Z, Kirschner J, Mercuri E, Farrar MA, Iannaccone ST, Kuntz NL, Finkel RS, Valente M, Muntoni F. Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model. CNS Drugs 2022. [PMID: 35080757 DOI: 10.1007/s40263-022-00899-0] [Reference Citation Analysis]
7 Ferrantini G, Coratti G, Onesimo R, Lucibello S, Bompard S, Turrini I, Cicala G, Caprarelli M, Pera MC, Bravetti C, Berti B, Giorgio V, Bruno C, Brolatti N, Panicucci C, D’amico A, Longo A, Leoni C, Sansone VA, Albamonte E, Messina S, Sframeli M, Bertini E, Pane M, Mercuri E; the Italian ISMAC study group. Body mass index in type 2 spinal muscular atrophy: a longitudinal study. Eur J Pediatr. [DOI: 10.1007/s00431-021-04325-3] [Reference Citation Analysis]
8 Brunet de Courssou JB, Durr A, Adams D, Corvol JC, Mariani LL. Antisense therapies in neurological diseases. Brain 2021:awab423. [PMID: 35286370 DOI: 10.1093/brain/awab423] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Mercuri E. Spinal muscular atrophy: from rags to riches. Neuromuscul Disord 2021;31:998-1003. [PMID: 34736637 DOI: 10.1016/j.nmd.2021.08.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Coratti G, Cutrona C, Pera MC, Bovis F, Ponzano M, Chieppa F, Antonaci L, Sansone V, Finkel R, Pane M, Mercuri E. Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis. Orphanet J Rare Dis 2021;16:430. [PMID: 34645478 DOI: 10.1186/s13023-021-02065-z] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
11 Lippross S, Girmond P, Lüders KA, Austein F, Braunschweig L, Lüders S, Tsaknakis K, Lorenz HM, Hell AK. Smaller Intervertebral Disc Volume and More Disc Degeneration after Spinal Distraction in Scoliotic Children. J Clin Med 2021;10:2124. [PMID: 34068964 DOI: 10.3390/jcm10102124] [Reference Citation Analysis]
12 Stolte B, Nonnemacher M, Kizina K, Bolz S, Totzeck A, Thimm A, Wagner B, Deuschl C, Kleinschnitz C, Hagenacker T. Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters. J Neurol 2021. [PMID: 33899154 DOI: 10.1007/s00415-021-10569-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Freigang M, Wurster CD, Hagenacker T, Stolte B, Weiler M, Kamm C, Schreiber-Katz O, Osmanovic A, Petri S, Kowski A, Meyer T, Koch JC, Cordts I, Deschauer M, Lingor P, Aust E, Petzold D, Ludolph AC, Falkenburger B, Hermann A, Günther R. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. Ann Clin Transl Neurol 2021;8:1049-63. [PMID: 33792208 DOI: 10.1002/acn3.51340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
14 Kim AR, Lee JM, Min YS, Lee H, Kim D, Hwang SK, Kwon S, Lee YJ. Clinical Experience of Nusinersen in a Broad Spectrum of Spinal Muscular Atrophy: A Retrospective Study. Ann Indian Acad Neurol 2020;23:796-801. [PMID: 33688130 DOI: 10.4103/aian.AIAN_524_20] [Reference Citation Analysis]
15 Lee J, Park SE, Lee D, Song JY, Lee J. Successful weaning from mechanical ventilation in a patient with SMA type 1 treated with nusinersen. Ann Clin Transl Neurol 2021;8:964-7. [PMID: 33616311 DOI: 10.1002/acn3.51321] [Reference Citation Analysis]
16 MacCannell D, Berger Z, East L, Mercuri E, Kirschner J, Muntoni F, Farrar MA, Peng J, Zhou J, Nestorov I, Farwell W, Finkel RS. Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen. Neuromuscul Disord 2021;31:310-8. [PMID: 33781694 DOI: 10.1016/j.nmd.2021.02.014] [Cited by in F6Publishing: 3] [Reference Citation Analysis]